Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations
Open Access
- 24 March 2022
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 292 (1) , 127-135
Abstract
Background: While COVID‐19 immunization programs attempted to reach targeted rates, cases rose significantly since the emergence of the delta variant. This retrospective cohort study describes the correlation between antispike antibodies and outcomes of hospitalized, breakthrough cases during the delta variant surge.Methods: All patients with positive SARS‐CoV‐2 polymerase chain reaction hospitalized at Mayo Clinic Florida from 19 June 2021 to 11 November 2021 were considered for analysis. Cases were analyzed by vaccination status. Breakthrough cases were then analyzed by low and high antibody titers against SARS‐CoV‐2 spike protein, with a cut‐off value of ≥132 U/ml. Outcomes included hospital length of stay (LOS), need for intensive care unit (ICU), mechanical ventilation, and mortality. We used 1:1 nearest neighbor propensity score matching without replacement to assess for confounders.Results: Among 627 hospitalized patients with COVID‐19, vaccine breakthrough cases were older with more comorbidities compared to unvaccinated. After propensity score matching, the unvaccinated patients had higher mortality (27 [28.4%] vs. 12 [12.6%], p = 0.002) and LOS (7 [1.0–57.0] vs. 5 [1.0–31.0] days, p = 0.011). In breakthrough cases, low‐titer patients were more likely to be solid organ transplant recipients (16 [34.0%] vs. 9 [12.3%], p = 0.006), with higher need for ICU care (24 [51.1%] vs. 22 [11.0%], p = 0.034), longer hospital LOS (median 6 vs. 5 days, p = 0.013), and higher mortality (10 [21.3%] vs. 5 [6.8%], p = 0.025) than high‐titer patients.Conclusions: Hospitalized breakthrough cases were more likely to have underlying risk factors than unvaccinated patients. Low‐spike antibody titers may serve as an indicator for poor prognosis in breakthrough cases admitted to the hospital.Keywords
This publication has 22 references indexed in Scilit:
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccinationAmerican Journal of Transplantation, 2021
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virusAmerican Journal of Transplantation, 2021
- Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular ScreeningClinical Infectious Diseases, 2021
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patientsAnnals of Medicine, 2020
- Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaquesScience, 2020
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 InfectionThe Journal of Immunology, 2020